Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells 5,000 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) Director Jeffrey W. Albers sold 5,000 shares of the firm's stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $102.28, for a total value of $511,400.00. Following the sale, the director now directly owns 157,557 shares in the company, valued at approximately $16,114,929.96. This trade represents a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock traded up $2.33 on Wednesday, hitting $104.89. 1,114,529 shares of the company were exchanged, compared to its average volume of 999,285. Blueprint Medicines Co. has a 1-year low of $72.24 and a 1-year high of $121.90. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $6.66 billion, a price-to-earnings ratio of -49.71 and a beta of 0.61. The company has a 50-day moving average price of $93.75 and a 200 day moving average price of $95.29.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The company had revenue of $128.20 million during the quarter, compared to analysts' expectations of $127.56 million. During the same period in the prior year, the business earned ($2.20) EPS. The firm's quarterly revenue was up 126.5% on a year-over-year basis. As a group, sell-side analysts predict that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Stephens restated an "overweight" rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. HC Wainwright restated a "buy" rating and set a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, November 15th. JPMorgan Chase & Co. began coverage on shares of Blueprint Medicines in a research report on Thursday, November 14th. They issued an "overweight" rating and a $126.00 price objective for the company. UBS Group initiated coverage on Blueprint Medicines in a research note on Thursday, October 24th. They issued a "neutral" rating and a $88.00 price target for the company. Finally, StockNews.com upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Blueprint Medicines presently has a consensus rating of "Moderate Buy" and an average target price of $122.72.

Hedge Funds Weigh In On Blueprint Medicines

Several institutional investors and hedge funds have recently bought and sold shares of the company. Quarry LP purchased a new stake in shares of Blueprint Medicines during the 3rd quarter valued at approximately $32,000. Covestor Ltd increased its stake in Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 403 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Blueprint Medicines in the third quarter valued at $108,000. Values First Advisors Inc. acquired a new position in shares of Blueprint Medicines in the 3rd quarter valued at $122,000. Finally, CWM LLC grew its holdings in shares of Blueprint Medicines by 69.2% during the 3rd quarter. CWM LLC now owns 1,870 shares of the biotechnology company's stock worth $173,000 after purchasing an additional 765 shares during the period.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.